I’m going to say something that might surprise you: I’m not against Ozempic.
I’m doing this thing without it, yeah. Forty days of bedtime yoga, two scoops of protein powder in my morning coffee, logging every meal, losing 18 pounds the slow and boring way. No injections. No prescriptions. Just me, a yoga mat, and a lot of willpower-based complaining.
But I’ve been watching the cultural conversation around GLP-1 drugs blow up for the past year, and I realized I was forming opinions about something I didn’t fully understand. That felt intellectually dishonest. So I went and actually read the research.
This is part one of a three-part series. Here’s what Ozempic and its cousins actually do, where they came from, and what they were built for.
The Origin Story #
Semaglutide (brand names Ozempic and Wegovy) is a synthetic version of a hormone your gut already makes. It’s called glucagon-like peptide-1, or GLP-1, and your intestines release it naturally every time you eat. When GLP-1 shows up, your pancreas gets the signal to release insulin, your blood sugar stabilizes, and your brain gets told that food has arrived.
The drug mimics this signal but lasts much longer. Natural GLP-1 has a half-life of about 2 minutes. Semaglutide has a half-life of about a week, which is why you only inject it once a week.
The original, legitimate use case was type 2 diabetes. Ozempic was FDA-approved in 2017 to improve blood sugar control in adults with T2D. And the data there is genuinely impressive. A 2024 head-to-head trial published in Nature Metabolism found semaglutide produced meaningfully larger improvements in fasting glucose, postprandial insulin secretion, and HbA1c than the comparison diabetes medication. It’s a good drug for the condition it was designed for.
Then in 2021, a higher-dose version called Wegovy got approved specifically for weight management. And things started moving fast.
What It Does to Your Brain #
Here’s the part that I find genuinely fascinating, and that most of the discourse leaves out.
GLP-1 appetite suppression is not just “feeling full faster.” I wrote about what hunger actually feels like on a calorie deficit, and these drugs fundamentally rewire that signal. Here’s the mechanism. What’s actually happening is more interesting.
GLP-1 receptors are distributed throughout your gut, pancreas, and central nervous system. The drug activates receptors in multiple regions of your brain simultaneously:
The arcuate nucleus of the hypothalamus: This is your brain’s hunger control center. GLP-1 directly activates POMC/CART neurons, the ones that say “stop eating,” and indirectly suppresses NPY/AgRP neurons, the ones that say “start eating.” You’re stepping on the brake and lifting the foot off the gas at the same time.
The brainstem’s nucleus tractus solitarius: This region receives gut-to-brain satiety signals via the vagus nerve. GLP-1 amplifies these signals.
The mesolimbic reward system: This is the part that explains something GLP-1 users frequently report, that food just becomes less interesting. Not just “I’m full,” but “I don’t really want it.” GLP-1 receptors exist in the brain’s dopamine reward circuits. When you suppress those, you’re not just eating less food, you’re caring less about it.
A 2024 study also identified a newer mechanism in the dorsomedial hypothalamus: GLP-1 receptor neurons there create a kind of anticipatory satiation. Like your brain learns to predict fullness before the meal is even finished.
The point is: this is a multi-level neurological intervention. That doesn’t make it good or bad. It makes it something worth understanding.
The Cardiovascular Finding #
In 2023, a trial called SELECT was published in the New England Journal of Medicine. It’s worth knowing about.
The study gave semaglutide to people with established cardiovascular disease and obesity, but without diabetes. Not a T2D population. They tracked cardiovascular death, nonfatal heart attacks, and nonfatal strokes over about 40 months.
Semaglutide significantly reduced that composite outcome.
This isn’t trivial. It means the drug’s benefit for high-risk obese patients extends beyond blood sugar control. The FDA now includes reducing cardiovascular events in adults with established heart disease as an official indication for Ozempic in T2D patients.
Who It’s Actually Approved For #
This is where it gets relevant to the cultural conversation.
The FDA criteria for Wegovy (the weight management version) are:
- BMI of 30 or higher (obesity), OR
- BMI of 27 to 29.9 (overweight) with at least one weight-related comorbidity: hypertension, type 2 diabetes, dyslipidemia, or sleep apnea
And in December 2025, the WHO issued its first-ever global guideline on GLP-1 drugs for obesity. Their recommendation: BMI 30 or higher, as part of a comprehensive approach that includes healthy diet, physical activity, and professional support.
Not “I want to lose 15 pounds before the wedding.” Not “my doctor at the Hims app said I qualify.” Not a cosmetic intervention for people who are a bit soft around the middle.
The approved population is people with clinical obesity or overweight with a serious comorbidity, who are working with a healthcare provider, with diet and exercise as part of the plan.
That gap between what it’s approved for and how it’s actually being prescribed is where things get interesting. We’ll talk about that in part three.
Why I’m Writing This Series #
I’m losing weight the hard way. Not because medication is wrong, but because I started this without it and I’m genuinely curious whether the hard way works. So far it does. I’m down 18 pounds, 40 days on the exercise streak, 66 days without soda, and the belt just moved a notch.
But I’m not going to pretend medication doesn’t exist, or that it doesn’t work, or that everyone who uses it is taking the lazy way out. That’s not honest.
What I am going to do is tell you what the research actually says. Including the parts that don’t make the ads.
That’s part two.
Sources #
- Semaglutide vs dapagliflozin in type 2 diabetes (Nature Metabolism, 2024)
- STEP 1 trial: semaglutide for weight management (NEJM, 2021)
- GLP-1 increases preingestive satiation via hypothalamic circuits (Science, 2024)
- SELECT trial: semaglutide and cardiovascular outcomes (NEJM, 2023)
- WHO guideline on GLP-1 medicines for obesity (WHO, 2025)